Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jay Zhao
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Molecular Templates (United States)
ORCID:
0009-0001-0107-5712
Observed ORCID:
0009-0001-0107-5712
OpenAlex ID:
A5009418303
FDA Approval Summary: Teclistamab–A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma
2024
·
Andrea C. Baines
, Bindu Kanapuru
, et al.
·
Clinical Cancer Research
·
25
PDF
Abstract 3366: In vivo efficacy of a PD-L1 targeted, antigen seeding engineered toxin body
2020
·
Hilario J. Ramos
, Brigitte Brieschke
, et al.
·
Cancer Research
·
3
Abstract 1628: Engineered toxin bodies targeting PD-L1 to alter tumor immunophenotypes and deliver broad antigenic diversity and patient coverage
2021
·
Joseph D. Dekker
, Swati Khanna
, et al.
·
Cancer Research
·
2
Abstract 326: Engineered toxin bodies (ETBs) targeting Trop2
2022
·
Garrett L. Cornelison
, Adam Bartos
, et al.
·
Cancer Research
·
1
Abstract 539: Novel engineered toxin bodies targeting SLAMF7 (CS1)
2020
·
Aimee Iberg
, Garrett L. Cornelison
, et al.
·
Cancer Research
·
1
PD-L1 targeted engineered toxin body provides direct cytotoxicity and T-cell mediated tumor targeting.
2020
·
Roger J. Waltzman
, Brigitte Brieschke
, et al.
·
Journal of Clinical Oncology
·
1
Abstract 2661: Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile
2023
·
Chris Moore
, Lee Robinson
, et al.
·
Cancer Research
Abstract P4-08-18: Engineered Toxin Bodies Specific for TROP2 Positive Cancers
2023
·
Garrett L. Cornelison
, Ileana Pedraza
, et al.
·
Cancer Research
817 Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity
2022
·
Lauren Byrne
, Swati Khanna
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 335: c-KIT targeted ETBs for cancer therapy and HSC transplant conditioning
2022
·
Caleigh Howard
, Shu Wiley
, et al.
·
Cancer Research
Abstract 3538: A CTLA-4 targeted ETB for Treg depletion shows favorable preclinical efficacy and safety
2022
·
Asis Sarkar
, Rebecca Martin
, et al.
·
Cancer Research
Abstract 3543: Altering tumor immunophenotypes with PD-L1 engineered toxin bodies
2022
·
Swati Khanna
, Elizabeth M. Kapeel
, et al.
·
Cancer Research
Abstract 1627: Preclinical characterization of a novel CTLA-4-targeted ETB for direct Treg depletion
2021
·
Swati Khanna
, Caleigh Howard
, et al.
·
Cancer Research
Abstract 2278: CTLA-4 targeted engineered toxin bodies designed to deplete regulatory T cells (Tregs)
2020
·
Aimee Iberg
, Edith Acquaye-Seedah
, et al.
·
Cancer Research
Abstract 521: CD45 targeted engineered toxin bodies deplete hematopoietic and malignant cells
2020
·
Aimee Iberg
, Garrett L. Robinson
, et al.
·
Cancer Research
Show more works
View as search
Works count:
15
Citation count:
33
H-index:
2
I10-index:
1
Year
Topic
Type